LINC02360: A Potential Drug Target and Biomarker (G105374484)

Target Name: LINC02360

NCBI ID: G105374484

LINC02360

Other Name(s): Long intergenic non-protein coding RNA 2360 | long intergenic non-protein coding RNA 2360

LINC02360: A Potential Drug Target and Biomarker

Introduction

LINC02360 is a non-coding RNA (ncRNA) molecule that has been identified using RNA sequencing (RNA-seq) data. It is located within the last exon of the human intergenic non-protein coding RNA (iNPC) gene, which encodes for a protein involved in the regulation of cell growth and differentiation. The iNPC gene is located on chromosome 16, specifically on the q32 region.

The iNPC gene has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The non-coding RNA molecule, LINC02360, has been shown to play a crucial role in the regulation of iNPC gene expression.

Potential Drug Target

The iNPC gene is a promising drug target for various diseases. LINC02360 has been shown to be highly expressed in various tissues and cells, including cancer cells, neurobladder cells, and immune cells. It has also been shown to play a role in the regulation of iNPC gene expression.

The discovery of LINC02360 as a potential drug target has implications for the development of new treatments for various diseases. LINC02360 can be used as a biomarker to monitor disease progression and response to therapy. It can also be used as a target for small molecules, antibodies , or other therapeutic agents that can modulate its expression levels.

Biomarker

LINC02360 has been shown to be involved in the regulation of iNPC gene expression in various tissues and cells. It has been shown to be expressed in various biological processes, including cell growth, apoptosis, and inflammation. It has also been shown to play a role in the regulation of cellular pathways, including cell adhesion, migration, and the regulation of ion channels.

The expression of LINC02360 has been shown to be regulated by various factors, including DNA methylation, histone modification, and RNA-binding protein (RBP) interactions. It has also been shown to interact with various protein partners, including the transcription factor, p53.

Despite the potential benefits of LINC02360 as a drug target, more research is needed to fully understand its role in the regulation of iNPC gene expression and its potential as a biomarker. Further studies are needed to determine the efficacy and safety of targeting LINC02360 in various disease models, including animal models and human clinical trials.

Conclusion

LINC02360 is a non-coding RNA molecule that has been identified using RNA sequencing data. It is located within the last exon of the iNPC gene and has been shown to play a role in the regulation of iNPC gene expression. The potential drug target and biomarker has implications for the development of new treatments for various diseases. Further research is needed to fully understand its role in the regulation of iNPC gene expression and its potential as a biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2360

The "LINC02360 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02360 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets